Publicacions (40) Publicacions de INMACULADA PÉREZ CAMACHO

2024

  1. Long or complicated mpox in patients with uncontrolled HIV infection

    Journal of Medical Virology, Vol. 96, Núm. 3

  2. Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study

    The Lancet Microbe, Vol. 5, Núm. 4, pp. e390-e399

2023

  1. Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort

    Antibiotics, Vol. 12, Núm. 1

  2. Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial

    Open Forum Infectious Diseases, Vol. 10, Núm. 4

2022

  1. Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: The SARICOR Randomized Clinical Trial

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 2

  2. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 5, pp. 1452-1460

2021

  1. Epidemiologic changes in bloodstream infections in Andalucía (Spain) during the last decade

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 283.e9-283.e16

  2. Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)

    International Journal of Antimicrobial Agents, Vol. 58, Núm. 1

2020

  1. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): Protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

    BMJ Open, Vol. 10, Núm. 11

2019

  1. Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy

    Pharmacogenomics Journal, Vol. 17, Núm. 4, pp. 360-365

  2. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 35, Núm. 5, pp. 815-819

  2. Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study

    PLoS ONE, Vol. 11, Núm. 5

  3. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: The HEPAVIR SEG-HEP Cohort

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Evaluation of eosinophilia in immigrants in Southern Spain using tailored screening and treatment protocols: A prospective study

    Travel Medicine and Infectious Disease, Vol. 13, Núm. 4, pp. 315-321

2013

  1. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity

    Diabetes, Vol. 62, Núm. 12, pp. 4266-4269

  2. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  3. Incidence of Liver Damage of Uncertain Origin in HIV Patients Not Co-Infected with HCV/HBV

    PLoS ONE, Vol. 8, Núm. 7

  4. Recomendaciones de GESIDA/Secretaría del Plan Nacional sobre el Sida para el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2013)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 10, pp. 672-684